跳至主要内容
临床试验/CTRI/2023/08/057007
CTRI/2023/08/057007尚未招募Unknown

Effect of Bupropion on second generation antipsychotic induced weight gain and Melanocyte stimulating hormone (MSH) in patients with schizophrenia and its relationship with cognitive symptoms- An open label study. - NI

Central Institute of Psychiatry0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • In-patients satisfying the ICD-11 DCR criteria for schizophrenia.
  • First episode schizophrenia (2years)
  • Age 18-50yrs of both sexes.
  • BMI greater than or equal to 25 kg/m2
  • CDSS score <6 to rule out secondary negative symptoms.
  • Those who give written informed consent for participating in the study.

排除标准

  • Any other drug(except for Antipsychotics) that can cause weight gain.
  • Patients on 1st generation antipsychotics and or on 1st generation depot antipsychotics.
  • Co-morbid endocrine and/or cardiovascular conditions.
  • Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine and caffeine.
  • Known hypersensitivity to Tab. Bupropion or any of its components.
  • Deranged liver function test ( ALT greater than/equal to 180 IU/L and/or AST greater than/equal to 140 IU/L)
  • Significant current/past medical or neurological illness including severe hepatic disease and history of severe head injury.
  • Patients currently receiving ECT.
  • Treatment resistant schizophrenia patients or patients on clozapine.
  • History of suicidality (intent/attempt)
  • QTc interval greater than/equal to 450ms in males and greater than/equal to 470ms in females on Electrocardiogram (ECG).

研究者

相似试验